ASCO 2022 Conference Coverage
Avatar

ASCO 2022 Efficacy & Safety Results From the Phase 3 ASCEMBL Study of Asciminib vs. Bosutinib in CP-CML After ≥2 Prior TKIs: Week 96 Update

By ASCO 2022 Conference Coverage FEATURING Jorge Cortés
By ASCO 2022 Conference Coverage FEATURING Jorge Cortés
269 views
July 12, 2022
Comments 0
Login to view comments. Click here to Login

Featured Video

16:51
Incyte

Effects of PV Treatment on White Blood Cell Count and Thrombotic Risk

Feat. C. Harrison

Featured Video

07:44
Incyte

Optimizing the Management of Patients with Polycythemia Vera (PV)

Feat. P. Bose, R. Rampal

Recommended

24:44

State of the Art in 2024: Emerging Therapies in Hematologic Malignan…

Indy Hematology Review

R. Birhiray

878 views

·

6 months ago
09:51

MRD Testing in Leukemias: When Negativity Is a Positive Thing

i3 Health

N. S. Raje

463 views

·

7 months ago
04:16

Efficacy and Safety of Asciminib in Ph+ CML

Luke Fletcher

946 views

·

11 months ago
23:15

Is Post-HSCT Maintenance the SOC for AML?

Rush University Medical Center

M. Levis

298 views

·

5 months ago
07:55

ASH 2023 Insights: "Treatment Patterns & Clinical Outcomes Among Pat…

Insights from 2023 ASH Annual Meeting

E. Atallah

633 views

·

10 months ago
16:25

SOHO 2023: The New ELN Laboratory Recommendations for the Diagnosis …

SOHO 2023 Eleventh Annual Meeting

N. Cross

428 views

·

1 year ago
33:56

Experts Discuss How They Use Asciminib in Their CML Practice

MyCancerHaven

R. Vij, J. Zeidner

150 views

·

2 months ago
25:44

New

Myeloid Malignancies: Hot Topics in 2024

Yale Cancer Center

N. Podoltsev

129 views

·

3 weeks ago
19:15

SOHO 2023: CML - Are We Doing It Right?

SOHO 2023 Eleventh Annual Meeting

J. Cortés

351 views

·

1 year ago
17:30

SOHO 2023: Rational TKI Choice in CML

SOHO 2023 Eleventh Annual Meeting

M. Deininger

306 views

·

1 year ago
12:09

Treating Fibrosis and Inflammation in GvHD

Pooja Khandelwal

234 views

·

7 months ago
17:51

Chronic GVHD: A Case-Based Discussion

Penn Medicine Cellicon Valley '23: The Future of Cell and Gene Therapies

L. Perry

444 views

·

1 year ago
17:47

Treating CML Patients With TKI Resistance vs. TKI Intolerance

The University of Alabama at Birmingham School of Medicine

O. Jamy

297 views

·

1 year ago
16:52

Updates on Myeloproliferative Neoplasms Including CML

Winship Cancer Institute - Emory University

A. Hunter

136 views

·

6 months ago
27:47

Chronic GVHD: Review Advances in Prevention, Novel Endpoints, and Ta…

City of Hope

I. Amanam

199 views

·

8 months ago
20:43

Controversies in the Management of CML in 2024

Indy Hematology Review

R. Larson

109 views

·

6 months ago
11:02

ASH 2023 Insights: "Asciminib Combined With Dasatinib and Prednisone…

Insights from 2023 ASH Annual Meeting

M. Luskin

205 views

·

10 months ago
24:31

Current Treatment Landscape in Myeloid Malignancies

Houston Methodist

S. Shah

49 views

·

2 months ago
23:06

Understanding and Addressing the Challenges in CML in 2024

Indy Hematology Review

R. Larson

67 views

·

6 months ago
06:26

Managing TKI AEs in CML: Thrombocytopenia, Hypertension, Pancreatic …

Akriti Jain

89 views

·

10 months ago
AUTOPLAY